First-Line Antidepressants Produce Similar Responses in Major Depressive Disorder
N. Parry, Radu V. Saveanu
Abstract
N. Parry, Radu V. Saveanu
Abstract
This article presents results from the first half of the randomized controlled International Study to Predict Optimized Treatment in Depression [iSPOT-D; NCT00693849]. The study demonstrated that, for patients with major depressive disorder, escitalopram, sertraline, and venlafaxine extended release produced similar treatment response rates, with mild and similar side effects.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
This article presents results from the first half of the randomized controlled International Study to Predict Optimized Treatment in Depression [iSPOT-D; NCT00693849]. The study demonstrated that, for patients with major depressive disorder, escitalopram, sertraline, and venlafaxine extended release produced similar treatment response rates, with mild and similar side effects.
Key concepts: Escitalopram, Sertraline, Venlafaxine, Major depressive disorder, Citalopram, Depression (economics), Psychiatry, Fluoxetine